WASHINGTON, May 05, 2010 (BUSINESS WIRE) -- Finkelstein Thompson LLP is investigating potential claims on behalf of shareholders of SenoRx Inc. ("SenoRx" or the "Company")(SENO) arising from the Company's announcement of its intent to merge with C. R. Bard Inc. ("C. R. Bard"). Under the terms of the agreement, SenoRx shareholders will receive $11.00 in cash for every share of SenoRx stock they own in a transaction valued at approximately $200 million.

The investigation is focused on the potential unfairness of the consideration to SenoRx's shareholders and the process by which SenoRx's Board of Directors considered and approved the transaction. C. R. Bard is only offering a 13.6% premium over the closing price of SenoRx the day before the announcement.

If you are interested in discussing your rights as a SenoRx shareholder, or have information relating to this investigation, please contact Finkelstein Thompson's Washington, DC offices at (877) 337-1050 or by email at This email address is being protected from spam bots, you need Javascript enabled to view it .